You are here: Home » News-CM » Companies » News
Business Standard

Suven Life Sciences secures two product patents

Capital Market 

One each from and Israel

announced that it has received one (1) product patent from (2513085) and one (1) product patent from (224652) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029 respectively.

The granted claims of the patents are from the mechanism of action include the class of selective Alpha4Beta2 and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with Neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.

With these new patents, Suven has a total of twenty three (23) granted patents from and twelve (12) granted patents from

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, October 18 2016. 10:13 IST